Does Ozempic Cause Stomach Paralysis (Gastroparesis)?

“Stomach paralysis” is the phrase that drives the Ozempic gastroparesis lawsuits and the scariest headlines — but it overstates what happens to most people. Here is the honest version. GLP-1 drugs slow gastric emptying on purpose — that delay is part of how they curb appetite, not a malfunction (Ozempic label, §12.2 ^[1]). In a smaller subset, that slowing becomes severe enough to look like clinical gastroparesis (delayed stomach emptying with persistent nausea, vomiting, bloating, and early fullness). A widely-cited 2023 pharmacovigilance study (Sodhi 2023, JAMA ^[2]) found GLP-1 users had a higher rate of a new gastroparesis diagnosis than people on a different weight-loss drug — adjusted hazard ratio 3.67 (95% CI 1.15–11.90) — a real but uncommon relative increase, and the study could not prove the drug caused every case. The reassuring part: the delay is generally reversible, and for long-acting GLP-1s the gastric-emptying effect even fades over time (tachyphylaxis) with continued dosing (Nauck 2021 ^[5]). Severe, persistent symptoms warrant evaluation. See also our piece on ileus and bowel obstruction (a separate, more serious bowel problem) and how long a GLP-1 stays in your system (the reversibility timeline).

The honest summary

• Slowed digestion is the intended effect, not a side effect. GLP-1 drugs deliberately delay gastric emptying — that is part of how they make you feel full and eat less. The Ozempic label states plainly that “semaglutide causes a delay of early postprandial gastric emptying” under Pharmacodynamics (§12.2 ^[1]).
• “Stomach paralysis” is a layperson term that overstates the typical course. True gastroparesis is a clinical diagnosis (delayed emptying confirmed on testing, with persistent symptoms). Most GLP-1 users get the expected, tolerable slowing — not paralysis.
• A real but uncommon relative increase in gastroparesis diagnoses exists. Sodhi 2023 (JAMA) reported an adjusted hazard ratio of 3.67 (95% CI 1.15–11.90) for gastroparesis on a GLP-1 versus bupropion-naltrexone ^[2]. The confidence interval is wide and the absolute number of cases was small.
• It is usually reversible. Documented cases improved after stopping the drug (Chaudhry 2024 ^[4]), and for long-acting GLP-1s the gastric-emptying delay itself attenuates over time even on therapy — “effects on gastric emptying decrease over time (tachyphylaxis)” (Nauck 2021 ^[5]). How fast it clears tracks the drug's long half-life.
• Red flags still matter. Persistent vomiting, severe bloating, or an inability to keep food or fluids down is not the “normal” slowing — it warrants medical evaluation, and the FDA added ileus to the semaglutide label's postmarketing section (§6.2 ^[1]).

What "stomach paralysis" means in the headlines

“Stomach paralysis” is the plain-English label that lawsuits and news coverage have attached to gastroparesis — literally “stomach paralysis” in Greek. The term is medically real, but it is being used loosely. Clinically, gastroparesis means the stomach empties abnormally slowly in the absence of a physical blockage, confirmed by a gastric-emptying study, and accompanied by chronic symptoms: nausea, vomiting (sometimes of food eaten hours earlier), early fullness, bloating, and upper-abdominal discomfort. The headline version flattens an important distinction — between the expected, dose-related slowing that nearly everyone on a GLP-1 experiences to some degree, and a diagnosable motility disorder that a much smaller subset develops.

What the evidence actually shows about gastroparesis risk

The most-cited number behind the lawsuits comes from Sodhi and colleagues, a 2023 research letter in JAMA ^[2]. Using a large U.S. health-claims database (PharMetrics Plus), they compared roughly 5,400 adults with obesity — but without diabetes — who were prescribed a GLP-1 for weight loss (semaglutide or liraglutide) against people prescribed bupropion-naltrexone, another weight-loss drug. After adjustment, GLP-1 users had a higher rate of several gastrointestinal diagnoses: gastroparesis, adjusted HR 3.67 (95% CI 1.15–11.90); bowel obstruction, HR 4.22 (1.02–17.40); and pancreatitis, HR 9.09 (1.25–66.00). Biliary disease was not statistically increased (HR 1.50, 95% CI 0.89–2.53). Read those numbers carefully: the relative increases are real, but the confidence intervals are very wide — a sign the actual case counts were small — and a claims-database study shows association, not proof of causation.

That nuance matters because relative risk without absolute risk is exactly how a headline becomes scarier than the science. A hazard ratio of 3.67 sounds alarming, but it is multiplying a low baseline rate — gastroparesis is an uncommon diagnosis to begin with, so a few-fold relative increase still leaves the absolute chance for any individual low. The study's own authors, in their published reply to letters, emphasized that the findings flag a signal worth monitoring rather than a high-probability outcome for the average patient ^[3]. Severe, treatment-limiting gastroparesis on a GLP-1 remains rare; the more common experience is the expected, manageable slowing.

Beyond pharmacovigilance, the mechanistic and case-level evidence fills in the picture. A 2024 case report in Cureus (Chaudhry 2024 ^[4]) documented a 53-year-old woman on weekly semaglutide whose endoscopies showed retained food despite an overnight fast — objective delayed emptying — with nausea and abdominal pain that resolved within a month of stopping the drug. That reversibility is the rule, not the exception, and it fits the pharmacology: gastric emptying is a receptor-mediated, dose-related effect, and removing the drug removes the brake.

Who is at higher risk

• Pre-existing motility problems. If your stomach already empties slowly — including prior functional dyspepsia or unexplained chronic nausea — adding a drug that slows emptying further can tip you over the line. Tell your prescriber.
• Longstanding or poorly-controlled diabetes. Diabetic gastroparesis from nerve damage is one of the most common causes of the condition independent of any drug, so people with diabetes start from a higher baseline and need closer attention to GI symptoms.
• Rapid dose escalation. Symptoms cluster after dose increases. Slower titration is a standard strategy to reduce GI intolerance.
• Procedures requiring an empty stomach. Because food can be retained, anesthesia and endoscopy guidance now flags GLP-1 use as a possible aspiration consideration — always tell your surgeon, anesthesiologist, or endoscopist that you are on one.

Red-flag symptoms that warrant evaluation

Mild, intermittent nausea, early fullness, or reduced appetite is the expected effect and usually eases with time and slower dosing. What is not expected — and warrants contacting your clinician or seeking care — is persistent, severe, or escalating GI illness. The line to watch is the difference between “I feel full and a bit queasy” and “I cannot keep anything down.”

Gastroparesis vs. ileus — not the same thing

These two get conflated, but they are different problems. Gastroparesis is delayed stomach emptying with no physical blockage — the stomach is sluggish. Ileus (and mechanical bowel obstruction) is when the intestines stop moving things along or are blocked — a more acute, more dangerous situation that can require hospitalization. The FDA added ileus to the semaglutide label's postmarketing experience section, alongside intestinal obstruction and severe constipation ^[1]. The Sodhi study found elevated signals for both gastroparesis and bowel obstruction ^[2]. If your belly is swollen and painful and you cannot pass gas or stool, that is the ileus/obstruction picture — treat it as an emergency. We cover it in depth in our ileus and bowel obstruction article.

Bottom line

GLP-1 drugs slow digestion by design — that delayed gastric emptying is the mechanism behind the appetite control, and it is described under how the drug works, not as a defect (Ozempic label §12.2 ^[1]). A smaller subset develop more significant gastroparesis-type symptoms; pharmacovigilance data show a real but uncommon relative increase in gastroparesis diagnoses (adjusted HR 3.67, wide CI; association, not proof of cause) (Sodhi 2023 ^[2]). “Stomach paralysis” overstates the typical course for most users, and the effect is usually reversible — symptoms improve after stopping, and the delay even fades with continued dosing of long-acting agents (Chaudhry 2024 ^[4]; Nauck 2021 ^[5]). The right posture is neither panic nor dismissal: expect some slowing, know the red flags — persistent vomiting, severe bloating, inability to keep food down — and get evaluated if they appear.

This article is educational and is not medical advice. Every claim above is sourced to a peer-reviewed study, a published reply, or the current FDA label (via DailyMed), each verified against the live primary source before publication. Discuss your symptoms and medications with your own clinician.